As spotlight trains on biopharma diversity, most companies kept their C-suites exactly the same in 2020 — report
The past year has cast a harsh spotlight on the biopharma industry’s lack of diversity. And though most companies list diversity and inclusion as one of their key values, a whopping 67% of companies saw little or no change in representation by race or ethnicity at the executive level, according to a recent BIO survey.
As part of its second annual diversity report, BIO partnered with Coqual (formerly known as Center for Talent Innovation) to survey 100 companies from October to December 2020. They received organization-level diversity data from 18 companies, and executive-level diversity data from 16. Seventy percent of respondents listed D&I as one of their stated values, BIO said. But only 13% actually increased representation for executives of color by at least 5%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
